Maxim Group Upgrades Palisade Bio to Buy, Announces $1.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Naz Rahman has upgraded Palisade Bio (NASDAQ:PALI) from Hold to Buy and set a price target of $1.5 for the company's stock.

November 17, 2023 | 12:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Palisade Bio's stock has been upgraded by Maxim Group from Hold to Buy with a new price target of $1.5, indicating a positive outlook for the stock.
Analyst upgrades typically lead to a positive short-term reaction in the stock market as they suggest improved prospects for the company. The new price target of $1.5 by Maxim Group is likely to set a bullish tone for Palisade Bio's stock in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100